NASDAQ:PCRX Pacira BioSciences (PCRX) Stock Price, News & Analysis $14.54 +0.21 (+1.47%) (As of 09/27/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Pacira BioSciences alerts: Email Address About Pacira BioSciences Stock (NASDAQ:PCRX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Pacira BioSciences alerts:Sign Up Key Stats Today's Range$14.19▼$14.7550-Day Range$11.70▼$22.3652-Week Range$11.16▼$35.95Volume632,728 shsAverage Volume1.14 million shsMarket Capitalization$670.73 millionP/E Ratio10.17Dividend YieldN/APrice Target$24.10Consensus RatingHold Company OverviewPacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.Read More… WARNING: “Buffett Indicator” flashing for first time in 50 years (Ad)The stock market collapsed and didn't recover for an entire decade. And what we're facing today could be even worse. That's why the actions you take in the next 90 days could be crucial for your financial future.Take these 4 steps today to protect your retirement NOW Pacira BioSciences Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks96th Percentile Overall ScorePCRX MarketRank™: Pacira BioSciences scored higher than 96% of companies evaluated by MarketBeat, and ranked 39th out of 999 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingHold Consensus RatingPacira BioSciences has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 4 buy ratings, 4 hold ratings, and 2 sell ratings.Amount of Analyst CoveragePacira BioSciences has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Pacira BioSciences' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth-11.61% Earnings GrowthEarnings for Pacira BioSciences are expected to decrease by -11.61% in the coming year, from $2.24 to $1.98 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pacira BioSciences is 10.17, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 116.73.Price to Earnings Ratio vs. SectorThe P/E ratio of Pacira BioSciences is 10.17, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 103.79.Price to Book Value per Share RatioPacira BioSciences has a P/B Ratio of 0.78. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Pacira BioSciences' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.46% of the outstanding shares of Pacira BioSciences have been sold short.Short Interest Ratio / Days to CoverPacira BioSciences has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Pacira BioSciences has recently decreased by 4.96%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPacira BioSciences does not currently pay a dividend.Dividend GrowthPacira BioSciences does not have a long track record of dividend growth. Sustainability and ESG3.9 / 5Environmental Score-1.89 Percentage of Shares Shorted12.46% of the outstanding shares of Pacira BioSciences have been sold short.Short Interest Ratio / Days to CoverPacira BioSciences has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Pacira BioSciences has recently decreased by 4.96%, indicating that investor sentiment is improving. News and Social Media2.1 / 5News Sentiment0.69 News SentimentPacira BioSciences has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Pacira BioSciences this week, compared to 4 articles on an average week.MarketBeat FollowsOnly 3 people have added Pacira BioSciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Pacira BioSciences insiders have bought 29.14% more of their company's stock than they have sold. Specifically, they have bought $136,240.00 in company stock and sold $105,494.00 in company stock.Percentage Held by InsidersOnly 6.40% of the stock of Pacira BioSciences is held by insiders.Percentage Held by Institutions99.73% of the stock of Pacira BioSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Pacira BioSciences' insider trading history. Receive PCRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pacira BioSciences and its competitors with MarketBeat's FREE daily newsletter. Email Address PCRX Stock News HeadlinesExecutive reshuffles: NSC, PCRX and OMI Companies in focusSeptember 28 at 4:21 PM | msn.comPacira BioSciences appoints Lauren Riker as interim CFOSeptember 27 at 9:08 PM | msn.comWARNING: “Buffett Indicator” flashing for first time in 50 yearsThe stock market collapsed and didn't recover for an entire decade. And what we're facing today could be even worse. That's why the actions you take in the next 90 days could be crucial for your financial future.September 29, 2024 | Behind the Markets (Ad)Pacira BioSciences (NASDAQ:PCRX) Shares Gap Up on Analyst UpgradeSeptember 27 at 1:32 AM | americanbankingnews.comPacira Announces the Presentation of 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the KneeSeptember 26 at 8:00 AM | globenewswire.comDOMA Perpetual Sends Letter to Board of Directors of Pacira Biosciences to Immediately Accelerate and Increase its Share Buyback Program to Enhance Return to ShareholdersSeptember 25, 2024 | prnewswire.comPacira BioSciences (NASDAQ:PCRX) Price Target Raised to $18.00 at Jefferies Financial GroupSeptember 25, 2024 | americanbankingnews.comPacira BioSciences (NASDAQ:PCRX) Shares Up 6.7%September 19, 2024 | americanbankingnews.comSee More Headlines PCRX Stock Analysis - Frequently Asked Questions How have PCRX shares performed this year? Pacira BioSciences' stock was trading at $33.74 on January 1st, 2024. Since then, PCRX shares have decreased by 56.9% and is now trading at $14.54. View the best growth stocks for 2024 here. How were Pacira BioSciences' earnings last quarter? Pacira BioSciences, Inc. (NASDAQ:PCRX) released its quarterly earnings data on Tuesday, July, 30th. The company reported $0.64 earnings per share for the quarter, beating analysts' consensus estimates of $0.53 by $0.11. The company earned $178.02 million during the quarter, compared to analysts' expectations of $173.31 million. Pacira BioSciences had a trailing twelve-month return on equity of 13.22% and a net margin of 9.21%. How do I buy shares of Pacira BioSciences? Shares of PCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Pacira BioSciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pacira BioSciences investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD), Skyworks Solutions (SWKS), AbbVie (ABBV) and Pfizer (PFE). Company Calendar Last Earnings7/30/2024Today9/29/2024Next Earnings (Estimated)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:PCRX CUSIP69512710 CIK1396814 Webwww.pacira.com Phone(813) 553-6680Fax302-655-5049Employees720Year FoundedN/APrice Target and Rating Average Stock Price Target$24.10 High Stock Price Target$57.00 Low Stock Price Target$8.00 Potential Upside/Downside+65.7%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)$1.43 Trailing P/E Ratio10.17 Forward P/E Ratio6.49 P/E GrowthN/ANet Income$41.96 million Net Margins9.21% Pretax Margin14.56% Return on Equity13.22% Return on Assets7.24% Debt Debt-to-Equity Ratio0.67 Current Ratio6.82 Quick Ratio5.70 Sales & Book Value Annual Sales$674.98 million Price / Sales0.99 Cash Flow$4.04 per share Price / Cash Flow3.60 Book Value$18.74 per share Price / Book0.78Miscellaneous Outstanding Shares46,130,000Free Float43,567,000Market Cap$670.73 million OptionableOptionable Beta0.84 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report This page (NASDAQ:PCRX) was last updated on 9/29/2024 by MarketBeat.com Staff From Our PartnersWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredCongress passes legislation in favor of Musk-backed technology Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adopti...Porter & Company | SponsoredThe $15 "Insider Secret" That Could Save Your RetirementWhat if I told you there's a $15 stock that a billionaire insider just poured $47 MILLION into? That's righ...Behind the Markets | SponsoredKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppe...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pacira BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pacira BioSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.